Zura Bio Limited Class A Ordinary Shares Share Price
NASDAQ: ZURA | Small CapZura Bio Limited Class A Ordinary Shares Stock Performance
Open $5.50 | Prev. Close $5.78 | Circuit Range N/A |
Day Range $5.42 - $5.65 | Year Range $1.68 - $7.40 | Volume 62,627 |
Average Traded $5.56 |
Zura Bio Limited Class A Ordinary Shares Share Price Today
As of 16 August 2026, Zura Bio Limited Class A Ordinary Shares's share price is $5.58. The stock opened at $5.50, compared to its previous close of $5.78. During today's trading session, Zura Bio Limited Class A Ordinary Shares's share price traded between $5.42 and $5.65, with an average price of $5.54. Over the past 52 weeks, the stock has recorded a high of $7.40 and a low of $1.68. In terms of performance, Zura Bio Limited Class A Ordinary Shares's share price has declined by 15.45% over the last six months and is up 175.01% on a year-on-year basis.
Zura Bio Limited Class A Ordinary Shares Share Price Chart
Zura Bio Limited Class A Ordinary Shares Stock Fundamentals & Key Indicators
Market Cap $525.41M | PE Ratio (TTM) -5.26 | Dividend Yield N/A |
EPS (TTM) $-1.06 | Revenue (TTM) N/A | Return On Equity (TTM) -67.61% |
Profit Margin N/A | Debt to Equity 0.12 | Quarterly Earnings Growth YoY 12.86% |
Zura Bio Limited Class A Ordinary Shares Quarterly Profit & Loss
All figures in USD
Zura Bio Limited Class A Ordinary Shares Annual Profit & Loss
All figures in USD
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Zura Bio Limited Class A Ordinary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.43 | $5.58 | +2.86% |
Jul 2026 | $5.87 | $5.42 | -7.97% |
Jun 2026 | $4.25 | $5.89 | +37.09% |
May 2026 | $5.13 | $4.30 | -15.52% |
Apr 2026 | $5.97 | $5.09 | -14.17% |
Mar 2026 | $6.45 | $5.93 | -10.15% |
Feb 2026 | $5.67 | $6.60 | +15.59% |
Jan 2026 | $5.32 | $5.71 | +9.18% |
Dec 2025 | $3.67 | $5.23 | +35.14% |
Nov 2025 | $3.88 | $3.87 | +0.78% |
Oct 2025 | $4.29 | $3.84 | -10.70% |
Sep 2025 | $2.07 | $4.30 | +111.93% |
ZURA Share Price FAQs
What is Zura Bio Limited Class A Ordinary Shares share price today?
What is the 52 week high and 52 week low of Zura Bio Limited Class A Ordinary Shares stock?
What is ZURA's market capitalisation today?
What is ZURA's net income for the last quarter?
What is the 5 year returns of ZURA?
What is the high & low stock price of ZURA today?
Can I buy ZURA shares in India?